Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00991367
Other study ID # CAT-0909-CU
Secondary ID
Status Completed
Phase Phase 3
First received October 7, 2009
Last updated December 7, 2010
Start date October 2009
Est. completion date December 2010

Study information

Verified date December 2010
Source Catalysis SL
Contact n/a
Is FDA regulated No
Health authority Cuba: Institutional Review Board
Study type Interventional

Clinical Trial Summary

The purpose of the study is to assess the efficacy of CICATRIX (Asian Gotu Kola or Pennywort) usage in the treatment of recent post-surgical scars. The duration of this double-blind placebo controlled phase 3 clinical trial will be 4 weeks. The estimated number of persons to be recruited and randomized for the study is 90.


Recruitment information / eligibility

Status Completed
Enrollment 90
Est. completion date December 2010
Est. primary completion date December 2010
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 55 Years
Eligibility Inclusion Criteria:

- Recent (less than 48 hours) post-surgical wound

Exclusion Criteria:

- Post-surgical wound with sepsis

- Usage of steroids within 30 days

- Malignant neoplastic conditions

- Alcoholism

- Handicap and/or psychiatric condition preventing treatment accomplishment.

Study Design

Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Caregiver, Investigator), Primary Purpose: Treatment


Related Conditions & MeSH terms


Intervention

Other:
Cicatrix
Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of CICATRIX (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.
Placebo
Dosage commensurate with surface to be treated. After washing and drying the affected area, a thin layer of PLACEBO (Topical use) will be applied on the lesion rubbing in different directions for 2 minutes, three times a day, for 4 weeks.

Locations

Country Name City State
Cuba "Cdte. Manuel Fajardo Rivero" Clinical-Surgical-Docent Hospital Havana City Havana

Sponsors (1)

Lead Sponsor Collaborator
Catalysis SL

Country where clinical trial is conducted

Cuba, 

Outcome

Type Measure Description Time frame Safety issue
Primary Length of the post-surgical scar(s) measured by a millimetric ruler at week 4 (end of the treatment) 4 weeks No
Secondary Occurrence of adverse effects at week 4 (end of the treatment) 4 weeks Yes
Secondary Photographs of lesions at week 4 (end of the treatment) 4 weeks No
See also
  Status Clinical Trial Phase
Completed NCT02397564 - Treatment of Post-Surgical Scars With Traditional Ablative Er:YAG Versus Fractional Ablative Er:YAG N/A